Urinary biomarker discovery in gliomas using mass spectrometry-based clinical proteomics.

ABSTRACT:

Background

Gliomas are the most common primary malignant brain tumors and have a poor prognosis. Early detection of gliomas is crucial to improve patient outcomes. Urine accumulates systematic body changes and thus serves as an excellent early biomarker source.

Methods

At the biomarker discovery phase, we performed a self-controlled proteomics analysis by comparing urine samples collected from five glioma patients at the time of tumor diagnosis and after surgical removal of the tumor. At the biomarker validation phase, we further validated some promising proteins using parallel reaction monitoring (PRM)-based targeted proteomics in another cohort, including glioma, meningioma, and moyamoya disease patients as well as healthy controls.

Results

Using label-free proteome

SUBMITTER: Wu J 

PROVIDER: S-EPMC7398313 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature